Purchase this article with an account.
Weijun Wang, Lu Cheng, Shaopin Zhu, Xun Xu; Inhibition of uveitis by intravitreal injection of a small peptide derived from hepatocyte growth factor. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5413.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
H-K120 is a novel 20-amino-acid peptide indentified from the hepatocyte growth factor, a protein with protective effect against inflammatory diseases. In this study, we investigated the anti-inflammation effect of H-K120 in models of experimental ocular inflammation, icluding endotoxin induced uveitis (EIU) and experimental autoimmune uveitis (EAU), using in vitro and in vivo assays.
ELISA and RT-PCR were used to test the expression of cytokines; Clinical scoring and histological study were used to evaluate the inflammatory reaction of EIU and EAU in vivo; The expression of ICAM-1, VCAM-1, E-selectin, and phosphorylation of IKKα/β / IκBα / NF-κB was detected by immunofluorescence and immunoblot analyses.
Our results suggested that Our results suggested that intravitreal treatment of H-K120 concentration-dependently inhibited clinical manifestation, neutrophil infiltration and improved histopathologic scores in vivo. Moreover, H-K120 attenuated the LPS-induced mRNA and protein expression of interleukin (IL)-1beta, IL-6, IL-8 and tumor necrosis factor (TNF)-a in RAW 264.7 cells and inhibited cell chemotactic migration toward LPS. We also demonstrated that H-RN suppressed expression of adhesion molecule including ICAM-1, VCAM-1 and E-selectin in HUVECs. We also found the possible mechanism of H-K120 on uveitis was through interrupting the NF-κB pathway.
H-K120, a novel peptide derived from hepatocyte growth factor, may be a promising and safe drug for therapeutic application for corneal inflammation.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only